Tiered Categorization of a Diverse Panel of HIV-1 Env Pseudoviruses for Assessment of Neutralizing Antibodies
暂无分享,去创建一个
Holly Janes | David C Montefiori | Peter B Gilbert | Natalie Hawkins | Tanmoy Bhattacharya | John R Mascola | Marcus G Daniels | Michael S Seaman | A. Lapedes | B. Korber | J. Mascola | S. Self | D. Montefiori | Tanmoy Bhattacharya | F. McCutchan | M. Daniels | P. Gilbert | V. Polonis | R. Coffey | M. Seaman | H. Janes | Francine E McCutchan | B. Wood | Alan Lapedes | Bette T Korber | Blake Wood | Linda Harris | Victoria R Polonis | Lauren E Grandpre | Colleen Devoy | Ayush Giri | Rory T Coffey | Steve G Self | L. E. Grandpre | C. Devoy | A. Giri | Natalie R. Hawkins | Linda J. Harris
[1] S. Zeger,et al. Longitudinal data analysis using generalized linear models , 1986 .
[2] G. Shaw,et al. Molecular characterization of human T-cell leukemia (lymphotropic) virus type III in the acquired immune deficiency syndrome. , 1984, Science.
[3] Pamela G. Guren,et al. Candidates , 1982, Otolaryngology–Head and Neck Surgery.
[4] B. Haynes,et al. Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS. , 1984, Science.
[5] Lynn Morris,et al. Recommendations for the Design and Use of Standard Virus Panels To Assess Neutralizing Antibody Responses Elicited by Candidate Human Immunodeficiency Virus Type 1 Vaccines , 2005, Journal of Virology.
[6] J. Overbaugh,et al. HIV type 1 variants transmitted to women in Kenya require the CCR5 coreceptor for entry, regardless of the genetic complexity of the infecting virus. , 2002, AIDS research and human retroviruses.
[7] David C Montefiori,et al. Recent advances in the characterization of HIV-1 neutralization assays for standardized evaluation of the antibody response to infection and vaccination. , 2008, Virology.
[8] Joseph Sodroski,et al. Characterization of CD4-induced epitopes on the HIV type 1 gp120 envelope glycoprotein recognized by neutralizing human monoclonal antibodies. , 2002, AIDS research and human retroviruses.
[9] D. Montefiori,et al. Immunization with recombinant canarypox vectors expressing membrane-anchored glycoprotein 120 followed by glycoprotein 160 boosting fails to generate antibodies that neutralize R5 primary isolates of human immunodeficiency virus type 1. , 2000, AIDS research and human retroviruses.
[10] Robert Tibshirani,et al. Estimating the number of clusters in a data set via the gap statistic , 2000 .
[11] J. Mascola,et al. Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group. , 1996, The Journal of infectious diseases.
[12] Martin A. Nowak,et al. Antibody neutralization and escape by HIV-1 , 2003, Nature.
[13] Tahir A. Rizvi,et al. Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian–human immunodeficiency virus infection , 2000, Nature Medicine.
[14] D. Birx,et al. Differential role of V3-specific antibodies in neutralization assays involving primary and laboratory-adapted isolates of HIV type 1. , 1995, AIDS research and human retroviruses.
[15] J. Sodroski,et al. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody , 1998, Nature.
[16] J. Mascola,et al. Protection of Macaques against Pathogenic Simian/Human Immunodeficiency Virus 89.6PD by Passive Transfer of Neutralizing Antibodies , 1999, Journal of Virology.
[17] J. Kappes,et al. Sensitivity of Human Immunodeficiency Virus Type 1 to the Fusion Inhibitor T-20 Is Modulated by Coreceptor Specificity Defined by the V3 Loop of gp120 , 2000, Journal of Virology.
[18] Peter D. Kwong,et al. HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites , 2002, Nature.
[19] J. Mascola,et al. Soluble CD4 broadens neutralization of V3-directed monoclonal antibodies and guinea pig vaccine sera against HIV-1 subtype B and C reference viruses. , 2008, Virology.
[20] E. Sanders-Buell,et al. Biologic and Genetic Characterization of a Panel of 60 Human Immunodeficiency Virus Type 1 Isolates, Representing Clades A, B, C, D, CRF01_AE, and CRF02_AG, for the Development and Assessment of Candidate Vaccines , 2005, Journal of Virology.
[21] E. Sanders-Buell,et al. Cross-clade neutralization patterns among HIV-1 strains from the six major clades of the pandemic evaluated and compared in two different models. , 2008, Virology.
[22] L. Stamatatos,et al. Effect of major deletions in the V1 and V2 loops of a macrophage-tropic HIV type 1 isolate on viral envelope structure, cell entry, and replication. , 1998, AIDS research and human retroviruses.
[23] D. Burton,et al. GP120: target for neutralizing HIV-1 antibodies. , 2006, Annual review of immunology.
[24] Michael P Busch,et al. Dynamics of HIV viremia and antibody seroconversion in plasma donors: implications for diagnosis and staging of primary HIV infection , 2003, AIDS.
[25] Renate Kunert,et al. Comprehensive Cross-Clade Neutralization Analysis of a Panel of Anti-Human Immunodeficiency Virus Type 1 Monoclonal Antibodies , 2004, Journal of Virology.
[26] Hui Li,et al. Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection , 2008, Proceedings of the National Academy of Sciences.
[27] Mark Connors,et al. Broad HIV-1 neutralization mediated by CD4-binding site antibodies , 2007, Nature Medicine.
[28] Xiping Wei,et al. Human Immunodeficiency Virus Type 1 env Clones from Acute and Early Subtype B Infections for Standardized Assessments of Vaccine-Elicited Neutralizing Antibodies , 2005, Journal of Virology.
[29] Wayne C Koff,et al. HIV vaccine design and the neutralizing antibody problem , 2004, Nature Immunology.
[30] B. Chesebro,et al. Effects of CCR5 and CD4 Cell Surface Concentrations on Infections by Macrophagetropic Isolates of Human Immunodeficiency Virus Type 1 , 1998, Journal of Virology.
[31] D. Montefiori,et al. Evaluation of antiviral drugs and neutralizing antibodies to human immunodeficiency virus by a rapid and sensitive microtiter infection assay , 1988, Journal of clinical microbiology.
[32] Feng Gao,et al. Genetic and Neutralization Properties of Subtype C Human Immunodeficiency Virus Type 1 Molecular env Clones from Acute and Early Heterosexually Acquired Infections in Southern Africa , 2006, Journal of Virology.
[33] J. Mascola,et al. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies , 2000, Nature Medicine.
[34] J. Sodroski,et al. Role of vif in replication of human immunodeficiency virus type 1 in CD4+ T lymphocytes , 1992, Journal of virology.
[35] Lynn Morris,et al. Profiling the Specificity of Neutralizing Antibodies in a Large Panel of Plasmas from Patients Chronically Infected with Human Immunodeficiency Virus Type 1 Subtypes B and C , 2008, Journal of Virology.
[36] J. Mascola,et al. Efficient protein boosting after plasmid DNA or recombinant adenovirus immunization with HIV-1 vaccine constructs. , 2007, Vaccine.
[37] D. Ho,et al. Conformational epitope on gp120 important in CD4 binding and human immunodeficiency virus type 1 neutralization identified by a human monoclonal antibody , 1991, Journal of virology.
[38] D. Barouch,et al. Challenges in the development of an HIV-1 vaccine , 2008, Nature.
[39] S Gnanakaran,et al. Highly complex neutralization determinants on a monophyletic lineage of newly transmitted subtype C HIV-1 Env clones from India. , 2009, Virology.
[40] B. Haynes,et al. Aiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidates , 2006, Expert review of vaccines.
[41] Dennis R. Burton,et al. Toward an AIDS Vaccine , 2008, Science.
[42] J. Overbaugh,et al. Variants from the Diverse Virus Population Identified at Seroconversion of a Clade A Human Immunodeficiency Virus Type 1-Infected Woman Have Distinct Biological Properties , 1999, Journal of Virology.
[43] D. Montefiori,et al. Evaluating Neutralizing Antibodies Against HIV, SIV, and SHIV in Luciferase Reporter Gene Assays , 2004, Current protocols in immunology.
[44] T. Caliński,et al. A dendrite method for cluster analysis , 1974 .
[45] S. Zolla-Pazner,et al. Neutralization of primary human immunodeficiency virus type 1 isolates by the broadly reactive anti-V3 monoclonal antibody, 447-52D , 1994, Journal of virology.
[46] J. Moore,et al. HIV-1 neutralization: the consequences of viral adaptation to growth on transformed T cells. , 1995, AIDS.
[47] D. Heckerman,et al. Founder Effects in the Assessment of HIV Polymorphisms and HLA Allele Associations , 2007, Science.
[48] C. Cheng‐Mayer,et al. Antibody Protects Macaques against Vaginal Challenge with a Pathogenic R5 Simian/Human Immunodeficiency Virus at Serum Levels Giving Complete Neutralization In Vitro , 2001, Journal of Virology.